Results 21 to 30 of about 10,125,713 (289)

NAFLD‐related hepatocellular carcinoma: The growing challenge

Hepatology, EarlyView., 2022
Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison   +2 more
wiley   +1 more source

Lipocalin‐2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high‐fat diet–fed Ob/Ob mice

Hepatology, EarlyView., 2022
Graphical summary of obesity‐induced NASH progression by LCN2 targeted to HSC activation. Abstract Background and Aims In obesity and type 2 diabetes mellitus, leptin promotes insulin resistance and contributes to the progression of NASH via activation of hepatic stellate cells (HSCs).
Kyung Eun Kim, Jaewoong Lee, Hyun Joo Shin, Eun Ae Jeong, Hye Min Jang, Yu Jeong Ahn, Hyeong Seok An, Jong Youl Lee, Meong Cheol Shin, Soo Kyoung Kim, Won Gi Yoo, Won Ho Kim, Gu Seob Roh   +12 more
wiley   +1 more source

Myeloid p38 activation maintains macrophage–liver crosstalk and BAT thermogenesis through IL‐12–FGF21 axis

Hepatology, EarlyView., 2022
Physiological activation of myeloid p38 controls macrophage IL‐12 production and crosstalk to the liver by modulating hepatic FGF21, and subsequently, brown adipose tissue thermogenesis during obesity Abstract Obesity features excessive fat accumulation in several body tissues and induces a state of chronic low‐grade inflammation that contributes to ...
María Crespo, Ivana Nikolic, Alfonso Mora, Elena Rodríguez, Luis Leiva‐Vega, Aránzazu Pintor‐Chocano, Daniel Horrillo, Lourdes Hernández‐Cosido, Jorge L. Torres, Eva Novoa, Rubén Nogueiras, Gema Medina‐Gómez, Miguel Marcos, Magdalena Leiva, Guadalupe Sabio   +14 more
wiley   +1 more source

Elevated endotoxin levels in non-alcoholic fatty liver disease [PDF]

, 2010
Background: Emerging data indicate that gut-derived endotoxin may contribute to low-grade systemic inflammation in insulin resistant states. This study aimed to examine the importance of serum endotoxin and inflammatory markers in non-alcoholic fatty ...
Ashour, E., Steven J Creely, Youssef-Elabd, E., Youssef-Elabd, Elham M., Harte, A., Abdalla, M., Creely, S., Ashour Esmat, da Silva, Nancy F., McTernan Philip G, Mohga S Abdalla, Day, C.P., Day, Christopher Paul, Billyard, T., Burt, Alastair D., Burt Alastair D, Philip G McTernan, Kumar, S., Elham M Youssef-Elabd, da Silva, N.F., Alison L Harte, Burt, A.D., Nancy F da Silva, Amin, Ashraf I., Tripathi, Gyanendra, Sharada, H., Burt, A., McTernan, P. G., Billyard, Thomas, da Silva, N., Harte, A.L., Day Christopher P, Youssef-Elabd Elham M, Tripathi Gyanendra, Alastair D Burt, Sharada, Hayat M., Hayat M Sharada, Kumar Sudhesh, Abdalla Mohga S, Sharada, H.M., Day, C., Abdalla, Mohga S., Sudhesh Kumar, Creely, S.J., McGee Kirsty C, Esmat Ashour, McTernan, P., Abdalla, M.S., Tripathi, G., McGee, K.C., Youssef-Elabd, E.M., Kirsty C McGee, Christopher P Day, Ashour, Esmat, McGee, K., Billyard Thomas, Gyanendra Tripathi, Thomas Billyard, Kumar, Sudhesh, Amin Ashraf I, Amin, A., da Silva Nancy F, Harte, A. L., Ashraf I Amin, McTernan, P.G., Creely, Steven J., McGee, K. C., Harte Alison L, Creely Steven J, Sharada Hayat M, Amin, A.I.   +70 more
core   +1 more source

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

Hepatology, EarlyView., 2022
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen‐Chieh Chuang, Julie Lin, Wen‐Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris V. Kowdley, Aliya Gulamhusein, Christopher L. Bowlus, Ryan S. Huss, Robert P. Myers, Chuhan Chung, Andrew N. Billin   +20 more
wiley   +1 more source

Macrophage‐derived MLKL in alcohol‐associated liver disease: Regulation of phagocytosis

Hepatology, EarlyView., 2022
EtOH causes leaky gut allowing bacteria and PAMPs into the liver, resulting in hepatic inflammation and injury. We demonstrate that LPS induces STAT1‐mediated expression and phosphorylation of MLKL in macrophages and identify a novel function that myeloid MLKL translocates to phagosomes and lysosomes and regulates phagocytosis, which contributes to the
Xiaoqin Wu, Xiude Fan, Megan R. McMullen, Tatsunori Miyata, Adam Kim, Vai Pathak, Jianguo Wu, Le Z. Day, Josiah E. Hardesty, Nicole Welch, Jaividhya Dasarathy, Daniela S. Allende, Arthur J. McCullough, Jon M. Jacobs, Daniel M. Rotroff, Srinivasan Dasarathy, Laura E. Nagy   +16 more
wiley   +1 more source

Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness

Hepatology, EarlyView., 2022
Abstract Background and Aims Reliable noninvasive biomarkers are an unmet clinical need for the diagnosis of NASH. This study investigates the diagnostic accuracy of the circulating triggering receptor expressed on myeloid cells 2 (plasma TREM2) as a biomarker for NASH in patients with NAFLD and elevated liver stiffness.
Vineesh Indira Chandran, Charlotte Wilhelmina Wernberg, Mette Munk Lauridsen, Maria Kløjgaard Skytthe, Sofie Marchsteiner Bendixen, Frederik Tibert Larsen, Camilla Dalby Hansen, Lea Ladegaard Grønkjær, Majken Storm Siersbæk, Tina Di Caterino, Sönke Detlefsen, Holger Jon Møller, Lars Grøntved, Kim Ravnskjaer, Søren Kragh Moestrup, Maja Sofie Thiele, Aleksander Krag, Jonas Heilskov Graversen   +17 more
wiley   +1 more source

Machine learning to predict progression of non‐alcoholic fatty liver to non‐alcoholic steatohepatitis or fibrosis

JGH Open, 2022
Background Non‐alcoholic fatty liver (NAFL) can progress to the severe subtype non‐alcoholic steatohepatitis (NASH) and/or fibrosis, which are associated with increased morbidity, mortality, and healthcare costs.
Sina Ghandian, Rahul Thapa, Anurag Garikipati, Gina Barnes, Abigail Green‐Saxena, Jacob Calvert, Qingqing Mao, Ritankar Das   +7 more
doaj   +1 more source

Insulin sensitisers in the treatment of non-alcoholic fatty liver disease : a systematic review [PDF]

, 2011
Non-alcoholic fatty liver disease (NAFLD) is closely linked with obesity and the prevalence of NAFLD is about 17% to 33% in the Western world. There is a strong association of NAFLD with insulin resistance and, hence, insulin sensitisers have been tried.
C Clar, Henderson, R., Gurung, T., N Waugh, N Sattar, N Ghouri, Clar, C., Sattar, Naveed, Sattar, N., Fraser, A., T Gurung, Gurung, T. (Tara), D Shyangdan, A Fraser, Shyangdan, D., D Preiss, Waugh, Norman, Shyangdan, D. (Deepson), R Henderson, Ghouri, N., Preiss, D., Waugh, N.   +21 more
core   +1 more source

Diagnosis of Non-alcoholic fatty liver disease

Journal of Pathology of Nepal, 2016
Non Alcoholic Fatty Liver Disease is the deposition of fat in liver in absence of excessive of alcohol consumption. Non Alcoholic Fatty Liver Disease ranges from simple steatosis to Nonalcoholic steatohepatitis and cirrhosis.
Geetika K.C.
doaj   +1 more source